The anticipated haul will fund late-phase trials of NuCana’s reformulated cancer candidates, including a version of Eli Lilly’s Gemzar.
Destiny's IPO gives it £15.3 million to assess lead candidate XF-73 in the prevention of postsurgical staphylococcal infections in a phase 2b trial.
OrbiMed has launched its third Asia-focused biopharma and healthcare fund with more than half a billion dollars’ worth of private equity.
Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.
Corporate venture capital has long been an important source of capital for early-stage biotechs and shows no signs of diminishing.
Industry leaders put together the wish list to influence an upcoming deal between the sector and an increasingly interventionist government.
The West Coast biotech signed up new Chinese backers to expand its late-phase immuno-oncology program and move an anti-PD-1 antibody into the clinic.
After nearly a year and three term revisions, Accelerated Pharma is pulling its initial public offering.
MabVax Therapeutics is hiring an investment bank to help it find a buyer or sell off its assets as it continues to struggle for cash.
The financing gives Laura Deming, who started work on the fund before turning 18, $22 million to invest in companies working on age-related diseases.